Development guidelines for MAbs serve as a blueprint for their manufacture, safety, and efficacy testing.
Maria del Carmen Abrahantes-Pérez
Advertisement
Articles by Maria del Carmen Abrahantes-Pérez
Advertisement
Latest Updated Articles
GMP Compliance for Production of CB.Hep-1 Monoclonal Antibody as a Biological ReagentPublished: February 1st 2006 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
How Enzymatic Platforms May Change the Therapeutic RNA Supply Chain
2
Q&A: Strategies for Supply Chain Resilience and Next-Generation Process Optimization
3
BioPharm Weekly News Roundup—Week of Oct. 27, 2025
4
BioPharma By the Numbers: Bioprocess Hiring Creating Capacity Constraints
5
